Research Topics
| P N RuygrokSummaryAffiliation: Green Lane Hospital Country: New Zealand Publications
| Collaborators
|
Detail Information
Publications
Does angiography six months after coronary intervention influence management and outcome? Benestent II InvestigatorsP N Ruygrok
The Benestent Investigators and Cardialysis, Rotterdam, The Netherlands
J Am Coll Cardiol 34:1507-11. 1999..This study was performed to assess whether angiography six months after coronary balloon angioplasty or stent implantation has an influence on clinical management and one-year outcome...
Coronary angioplasty in New Zealand 1995-1998: a report from the National Coronary Angioplasty RegistryP N Ruygrok
Green Lane Hospital, Auckland
N Z Med J 113:381-4. 2000..To report coronary angioplasty data collected by the New Zealand Coronary Angioplasty Registry from 1995-1998...
Clinical and angiographic factors associated with asymptomatic restenosis after percutaneous coronary interventionP N Ruygrok
Cardialysis, Westblaak 92, 3012 KM Rotterdam, Netherlands
Circulation 104:2289-94. 2001..Clinical and angiographic factors associated with asymptomatic versus symptomatic restenosis after percutaneous coronary intervention were compared...
A randomized study of direct coronary stent delivery compared with stenting after predilatation: the NIR future trial. On behalf of the NIR Future Trial InvestigatorsJ A Ormiston
Green Lane Hospital, Auckland, New Zealand
Catheter Cardiovasc Interv 50:377-81; discussion 382-3. 2000..The clinical outcome at 1 month was satisfactory in both groups. In selected patients, a strategy of direct stenting is feasible, costs less, and is quicker to perform than the conventional strategy of stenting following predilatation...
Cardiac allograft vasculopathy: the green lane hospital experience 1987-1998S R Dixon
Department of Cardiology, Green Lane Hospital, Green Lane West, Auckland
N Z Med J 112:417-20. 1999..To determine the prevalence of cardiac allograft vasculopathy in heart transplant recipients at Green Lane Hospital and to examine potential risk factors for vasculopathy...
Rapamycin in cardiovascular medicineP N Ruygrok
Green Lane Hospital, Auckland, New Zealand
Intern Med J 33:103-9. 2003..Concerns regarding toxicity, carcinogenicity, delayed healing and endothelialization remain. As with any new agent or technology, we must remain vigilant to late adverse side-effects...
